Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
9.66B
Market cap9.66B
Price-Earnings ratio
-3.30
Price-Earnings ratio-3.30
Dividend yield
Dividend yield
Average volume
13.33M
Average volume13.33M
High today
$25.63
High today$25.63
Low today
$23.82
Low today$23.82
Open price
$23.94
Open price$23.94
Volume
15.65M
Volume15.65M
52 Week high
$75.37
52 Week high$75.37
52 Week low
$23.15
52 Week low$23.15

MRNA News

Benzinga 7h
Nio, Rivian, Moderna, Meta And Bitmine Immersion: Why These 5 Stocks Are On Investors' Radars Today

On Tuesday, U.S. markets slipped, with the Dow Jones Industrial Average falling about 0.3% to 45,757.90, the S&P 500 retreating 0.1% to 6,606.76, and the Nasdaq...

Nio, Rivian, Moderna, Meta And Bitmine Immersion: Why These 5 Stocks Are On Investors' Radars Today
Sherwood News 16h
Moderna is up on the release of positive results for reformulated Covid vaccine

Moderna is up on the release of positive results for reformulated Covid vaccine Moderna rose on Tuesday after it announced encouraging trial results for its ne...

Moderna is up on the release of positive results for reformulated Covid vaccine
Benzinga 18h
Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax

Moderna Inc. MRNA on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to h...

Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax

Analyst ratings

59%

of 27 ratings
Buy
22.2%
Hold
59.3%
Sell
18.5%

More MRNA News

TipRanks 22h
Moderna says clinical data reinforce FDA approval of 2025-2026 Spikevax formula

Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to hel...

Simply Wall St 3d
Why Is Moderna Facing Renewed Questions on Vaccine Oversight and Future Regulatory Risk?

In early September 2025, Moderna faced heightened scrutiny after reports surfaced that U.S. health officials plan to present claims linking COVID-19 vaccines to...

Why Is Moderna Facing Renewed Questions on Vaccine Oversight and Future Regulatory Risk?

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.